Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04843774 · ClinicalTrials.gov registry record
Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 64
- Enrollment target
NCT04843774 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 64 participants.
The verdict
NCT04843774 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic infection to mild flu-like symptoms to multi system failure and death, resulting in significant morbidity and mortality worldwide. Novel vaccines against the SARS-CoV-2 virus have very recently been developed; however, the effectiveness, immune response, and short- or long-term safety of these vaccines have not been tested in immunocompromised patients on anti-CD-20 therapy for multiple sclerosis (MS) or for other disorders. This study will examine the immune response of the Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus given as standard of care (SOC) in MS patients on ocrelizumab.
Interventions
- DRUG SARS-COV-2 mRNA Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2023-04-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04843774
The ClinicalTrials.gov registry entry for NCT04843774 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SARS-COV-2 mRNA Vaccine is the first listed.
NCT04843774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04843774 about?
NCT04843774 is a clinical study titled "Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)". Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic infection to mild flu-like symptoms to multi system failure and death, resulting in significant morbidity and mortality worldwid...
What is the current status of trial NCT04843774?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2021-04-20. Estimated completion is 2023-04-18.
What interventions are being tested in trial NCT04843774?
The interventions under investigation include: SARS-COV-2 mRNA Vaccine (DRUG).
Who is sponsoring clinical trial NCT04843774?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.